KCAS uses cutting edge technologies, including the Simoa by Quanterix, to address some of our client’s most challenging assay goals for PK and biomarker testing.
Our highly active method development team has developed and validated 4,600+ proprietary and 900+ non-proprietary bioanalytical assays.Read more
August 2018 KCAS Announces Hire of Director of BioPharma[press release]
June 2018 KCAS Announces Hire of Director of Bioanalytical Discovery Research Services [press release]
February 2018 KCAS Announces Hire of Vice President of Business Development[press release]
February 2018 KCAS Bioanalytical and Biomarker Welcomes Executive Director…